BMI View: Challenging political and macroeconomic conditions in the MENA region will continue tochallenge multinational drugmakers' performance and regional growth. This is dictating a number ofstrategic developments, including greater stakeholder engagement, new product launches and diversifiedtherapeutic development from firms in the region. Crucially, a country-specific approach is integral forpharmaceutical companies as they must adapt to the evolving pricing landscape, differing levels of patentprotection and the level of competition within each market.
Headline Expenditure Projections
Pharmaceuticals: USD31.7bn in 2016 to USD31.6bn in 2017. -0.5% y-o-y in US dollar terms.
Healthcare: USD170.2bn in 2016 to USD174.7bn in 2017. 2.7% y-o-y in US dollar terms.
The Middle East and North Africa (MENA) region will continue to present a diverse range of opportunitiesfor international drugmakers. While some markets present high growth potential and opportunities forinnovative product launches, it is vital that companies appreciate the varying levels of both investment riskand reward that are present in the markets in the region.